ZhiZengMDPhD
Internal Medicine • San Gabriel, CAPractice physician in internal medicine, and research scientist in longevity health.
Dr. Zeng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
316 E Las Tunas Dr Ste 102
San Gabriel, CA 91776Phone+1 626-300-8880Fax+1 626-300-8811- Is this information wrong?
Summary
- Physician Scientist with 24 years of clinical experience, and 30 years of scientific research expertise. primary focus on reverse aging, and longevity health using gene therapy and young plasma exchange therapy. Had successfully FDA IND filling as a Principal Investigator
Education & Training
Wayne State University School of MedicineResidency, Internal Medicine, 1996 - 1999
University of Michigan Medical SchoolClass of 1997, Postdoctoral Fellowship- Wayne State University School of MedicineClass of 1991, Ph.D.
Certifications & Licensure
CA State Medical License 1999 - 2025
OH State Medical License 2000 - 2001
MI State Medical License 1999 - 2000
Awards, Honors, & Recognition
- World Outstanding Chinese Award Canadian TV., 2019
- World Outstanding Oversea Chinese HTTV and Sino America Cultural exchange, 2018
Publications & Presentations
PubMed
- 41 citationsMxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells.Mary M. Taj, Rana J. Tawil, Lars D. Engstrom, Zhi Zeng, Clara Hwang, Martin G. Sanda, Daniel S. Wechsler> ;The Prostate. 2001 May 15
- 31 citationsInduction of Tumor Antigen-Specific Immunity In Vivo by a Novel Vaccinia Vector Encoding Safety-Modified Simian Virus 40 T AntigenYilin C. Xie, Clara Hwang, Willem W. Overwijk, Zhi Zeng, Marvin H. Eng, James J. Mulé, Michael J. Imperiale, Nicholas P. Restifo, Martin G. Sanda> ;Journal of the National Cancer Institute. 1999 Jan 20
- 46 citationsLongitudinal cohort analysis of lethal prostate cancer progression in transgenic mice.Chun X. Hsu, Brian D. Ross, Clarence E. Chrisp, Solomon Z. Derrow, Linda G. Charles, Kenneth J. Pienta, Norman M. Greenberg, Zhi Zeng, Martin G. Sanda> ;The Journal of Urology. 1998 Oct 1
Journal Articles
- A Novel Leflunomide Analog, UTL-5b (GBL-5b), Suppresses JAK3, MAP3K2, and LITAF GenesJiajiu Shaw1*, Ben Chen2, Paul Wooley2, Bruce Palfey3, An-Rong Lee4, Wen-Hsin Huang4, and Dustin Zhi Zeng, American Journal of Biomedical Sciences., 3/2011
- Anti-inflammatory and Anti-arthritic Effects of a Novel Leflunomide Analogue, UTL-5b (GBL5b)Jiajiu Shaw1, Ben Chen2, Paul Wooley2, Wen-Hsin Huang3, An-Rong Lee3 and Dustin Zhi Zeng4, American Journal of Biomedical Sciences., 3/2010
- Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase.Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zhi Zeng, Beidler DR, Poirier GG, Salvesen GS, Dixit VM., Cell, 6/1995
- Join now to see all
Grant Support
- Gene therapy for Prostate CancerVA1995–Present
Committees
- Scientific Advisory, Calerie Health 2021 - 2023
Research History
- Leading ScientistPartial Epigene reprogramming to achieve reversal of aging, using mRNA and AAV and young plasma methods (ongoing)2021 - 2023
- Principle InvestigatorStem Cell therapy for Covid-19 patient (FDA approved for clinical trial)2021 - 2022
- Chief ScientistStem Cell therapy for Diabetes2017 - 2021
- Co-Principle InvestigatorStem Cell therapy for knee arthritis Orthopedics, University of Southern California2017 - 2018
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
